Steven John Howson - Chief Executive Officer

Mr. Howson is an accomplished commercial executive with an impressive track record of delivering organisational growth, change management policy and governance within the pharmaceutical and healthcare sector, with a specific focus on the NHS. During his career Mr. Howson has held a number of commercial roles, both domestically and internationally and was, until recently, a Country General Manager (UK) within Ferring B.V., a company with a 5,000 strong workforce. Mr. Howson has a strong track record in strategic planning and both domestic and international expansion.

Jonathan Sumner - Chief Financial Officer

Mr. Sumner brings international experience in financial reporting and forecasting, tax, audit and M&A project management. He has held positions at PricewaterhouseCoopers, Ernst & Young and Deloitte and will be a key part of the Company's management team leading the development of the Healthperm business.


David James Sumner - Non-Executive Co-Chairman

David Sumner is a seasoned international entrepreneur with experience in sectors ranging from mining to healthcare and clean technology. He has served on numerous private and public company boards in both an executive and non-executive capacity and has a track record of raising capital through debt, pre-IPO and IPO. He is the founding shareholder of Healthperm Resourcing Ltd.

Alan William Norman Kitchin - Non-Executive Co-Chairman

Mr. Kitchin is a law graduate from Cambridge University where he was a Squire Law Scholar. Mr. Kitchin is an English solicitor and was a senior corporate partner in Ashurst LLP in London before being appointed managing partner of their Asia practice. He was subsequently headhunted to become a senior corporate partner at Clifford Chance LLP and has extensive experience of advising companies and their boards both in Asia and Europe. Mr. Kitchin has advised a number of medical and pharmaceutical companies on both corporate and regulatory issues and successful stock market listings. Mr. Kitchin holds a number of non-executive positions including as a non-executive director of the medical research company Reox Limited, which was spun out of Oxford University in 2003.

Aamir Ali Quraishi - Non-Executive Director

Mr. Quraishi has almost 20 years' of investment banking experience in Europe, Asia and the Middle East. He joined the corporate finance advisory division of Dresdner Kleinwort Benson in London in 1996 with some time also spent in Tokyo. He joined Libertas Capital Group plc in 2003, successfully building its capital markets practice and then relocated to its Dubai office in late 2007. Prior to his current role as a managing director of a NewYork headquartered advisory and investment banking firm, Mr. Quraishi worked with MAC Capital Limited, an investment bank operating out of the Dubai International Financial Centre. During his career, he has been involved in completed transactions with an aggregate value of over US$20 billion. Mr. Quraishi began his career at PwC in London where he qualified as a chartered accountant. Between 2005 and 2010, Mr. Quraishi was a qualified nominated adviser for the purposes of admissions to AIM. Mr. Quraishi is an Economics graduate from the University of Cambridge.

Lee Keen Whye - Non-Executive Director

Mr. Lee was appointed as a Non-Executive Director to Yujin in 2004. He is the Managing Director of Strategic Alliance Capital Pte Ltd, a venture capital and investment management advisory company. Mr. Lee has more than 30 years' experience in investment and fund management having started as an Investment Manager with the Government of Singapore Investment Corporation in 1982. In 1990 he founded Rothschild Ventures Asia Pte Ltd the venture capital operation of the N M Rothschild & Sons global merchant banking group in Asia and was its managing director until he left in 1997. He is on the board of several companies including Santak Holdings Ltd, Ntegrator International Ltd and Vard Holdings Limited which are listed on the Singapore Stock Exchange. Mr. Lee has a Master in Business Administration from Harvard Business School and a Bachelor of Business Administration from the University of Singapore.


Page last up-dated: 10 April 2018

Company Research

Share Price


as at 15:53:18 on 22/09/2018